Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 1;138(12):1241-1250.
doi: 10.1001/jamaophthalmol.2020.4206.

Clinical Phenotype and Course of PDE6A-Associated Retinitis Pigmentosa Disease, Characterized in Preparation for a Gene Supplementation Trial

Laura Kuehlewein  1   2 , Ditta Zobor  1 , Sten Olof Andreasson  3 , Carmen Ayuso  4   5 , Sandro Banfi  6 , Beatrice Bocquet  7   8 , Antje S Bernd  2 , Saskia Biskup  9 , Camiel J F Boon  10   11 , Susan M Downes  12 , M Dominik Fischer  1   2 , Frank G Holz  13 , Ulrich Kellner  14   15 , Bart P Leroy  16   17   18   19 , Isabelle Meunier  7   8 , Fadi Nasser  1 , Thomas Rosenberg  20 , Günther Rudolph  21 , Katarina Stingl  2 , Alberta A H J Thiadens  22 , Barbara Wilhelm  23 , Bernd Wissinger  24 , Eberhart Zrenner  1   25 , Susanne Kohl  24 , Nicole Weisschuh  24 ; RD-CURE Consortium
Affiliations

Clinical Phenotype and Course of PDE6A-Associated Retinitis Pigmentosa Disease, Characterized in Preparation for a Gene Supplementation Trial

Laura Kuehlewein et al. JAMA Ophthalmol. .

Abstract

Importance: Treatment trials require sound knowledge on the natural course of disease.

Objective: To assess clinical features, genetic findings, and genotype-phenotype correlations in patients with retinitis pigmentosa (RP) associated with biallelic sequence variations in the PDE6A gene in preparation for a gene supplementation trial.

Design, setting, and participants: This prospective, longitudinal, observational cohort study was conducted from January 2001 to December 2019 in a single center (Centre for Ophthalmology of the University of Tübingen, Germany) with patients recruited multinationally from 12 collaborating European tertiary referral centers. Patients with retinitis pigmentosa, sequence variants in PDE6A, and the ability to provide informed consent were included.

Exposures: Comprehensive ophthalmological examinations; validation of compound heterozygosity and biallelism by familial segregation analysis, allelic cloning, or assessment of next-generation sequencing-read data, where possible.

Main outcomes and measures: Genetic findings and clinical features describing the entire cohort and comparing patients harboring the 2 most common disease-causing variants in a homozygous state (c.304C>A;p.(R102S) and c.998 + 1G>A;p.?).

Results: Fifty-seven patients (32 female patients [56%]; mean [SD], 40 [14] years) from 44 families were included. All patients completed the study. Thirty patients were homozygous for disease-causing alleles. Twenty-seven patients were heterozygous for 2 different PDE6A variants each. The most frequently observed alleles were c.304C>A;p.(R102S), c.998 + 1G>A;p.?, and c.2053G>A;p.(V685M). The mean (SD) best-corrected visual acuity was 0.43 (0.48) logMAR (Snellen equivalent, 20/50). The median visual field area with object III4e was 660 square degrees (5th and 95th percentiles, 76 and 11 019 square degrees; 25th and 75th percentiles, 255 and 3923 square degrees). Dark-adapted and light-adapted full-field electroretinography showed no responses in 88 of 108 eyes (81.5%). Sixty-nine of 108 eyes (62.9%) showed additional findings on optical coherence tomography imaging (eg, cystoid macular edema or macular atrophy). The variant c.998 + 1G>A;p.? led to a more severe phenotype when compared with the variant c.304C>A;p.(R102S).

Conclusions and relevance: Seventeen of the PDE6A variants found in these patients appeared to be novel. Regarding the clinical findings, disease was highly symmetrical between the right and left eyes and visual impairment was mild or moderate in 90% of patients, providing a window of opportunity for gene therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Downes reported grants from Clinical Research Network NIHR Thames Valley during the conduct of the study; involvement with a commercial study on age-related macular degeneration with Allergan and Novartis; personal fees from Allergan, Circadian Therapeutics, and Boehringer Ingelheim; grants from Retina UK RP Genome outside the submitted work; and service as the chair of the medical advisory board for Retina UK. Dr Fischer reported being a director of Fischer Consulting Limited. Dr Kellner reported study support from Medspace/GTScope, Samsung, Bayer Vital, and Novartis and personal fees from Roche outside the submitted work. Dr Leroy reported grants and personal fees from GenSight Therapeutic, ProQR Therapeutics, and Novartis Pharma; personal fees from IVERIC Bio, Spark Therapeutics, REGENXBio, Biogen, and Vedere Bio; and grants from MeiraGTx outside the submitted work. Dr Stingl reported grants from Kerstan Foundation during the conduct of the study and grants from Retina Implant and personal fees from ProQR and Novartis outside the submitted work. Dr Leroy reports being a senior clinical investigator of the Research Foundation–Flanders (Belgium). Drs Wilhelm, Wissinger, Zrenner, Kohl, Kuehlewein, Weisschuh, and Zobor reported grants from Tistou and Charlotte Kerstan Foundation during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Genomic and Protein Structure of PDE6A and Location of Variants
The exon and intron organization is shown to scale at the top; the polypeptide and its functional domains, below. Blue indicates splice-site variants; black, frameshift variants; red, nonsense variants; gray, in-frame deletion or insertion; green, missense variants. cGMP indicates cyclic guanosine monophosphate; GAF, cGMP-specific phosphodiesterases, adenylyl cyclases and FhlA; PDE and PDEase, phosphodiesterase.
Figure 2.
Figure 2.. Visual Field Data
A and B, Visual field area at baseline for objects III4e and I4e. C, Visual field area of right eyes at baseline, and, if available, at last follow-up. Note the drop in visual field area that is most rapid in the second and third decades of life.
See this image and copyright information in PMC

Comment in

  • Moving Towards PDE6A Gene Supplementation Therapy.
    Bujakowska KM, Comander J. Bujakowska KM, et al. JAMA Ophthalmol. 2020 Dec 1;138(12):1251-1252. doi: 10.1001/jamaophthalmol.2020.4216. JAMA Ophthalmol. 2020. PMID: 33057571 Free PMC article. No abstract available.

References

    1. Retinal Information Network Table of contents. https://sph.uth.edu/retnet. Updated 2020. Accessed September 14, 2020.
    1. Huang SH, Pittler SJ, Huang X, Oliveira L, Berson EL, Dryja TP. Autosomal recessive retinitis pigmentosa caused by mutations in the alpha subunit of rod cGMP phosphodiesterase. Nat Genet. 1995;11(4):468-471. doi:10.1038/ng1295-468 - DOI - PubMed
    1. Dryja TP, Finn JT, Peng YW, McGee TL, Berson EL, Yau KW. Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa. Proc Natl Acad Sci U S A. 1995;92(22):10177-10181. doi:10.1073/pnas.92.22.10177 - DOI - PMC - PubMed
    1. Zhang X, Cote RH. cGMP signaling in vertebrate retinal photoreceptor cells. Front Biosci. 2005;10(1-3):1191-1204. doi:10.2741/1612 - DOI - PubMed
    1. Dryja TP, Rucinski DE, Chen SH, Berson EL. Frequency of mutations in the gene encoding the alpha subunit of rod cGMP-phosphodiesterase in autosomal recessive retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1999;40(8):1859-1865. - PubMed

Publication types

MeSH terms

Substances